Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.7355 EUR 2.65% Market Closed
Market Cap: 498.9m EUR
Have any thoughts about
Pharming Group NV?
Write Note

EV/EBIT
Enterprise Value to EBIT

-28.7
Current
6.4
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-28.7
=
Enterprise Value
448.6m EUR
/
EBIT
-16.5m USD
All Countries
Close
Market Cap EV/EBIT
NL
Pharming Group NV
AEX:PHARM
493.6m EUR -28.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -214 979.3
US
Abbvie Inc
NYSE:ABBV
299.8B USD 22.7
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD 27.6
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -505.7
AU
CSL Ltd
ASX:CSL
137.3B AUD 25.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 18.9
US
Seagen Inc
F:SGT
39.3B EUR -53.6
NL
argenx SE
XBRU:ARGX
34B EUR -75.7
EBIT Growth
NL
Pharming Group NV
AEX:PHARM
Average EV/EBIT: 23
Negative Multiple: -28.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 979.3 N/A
US
Abbvie Inc
NYSE:ABBV
22.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
25.8
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.7 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-31
2-Years Forward
EV/EBIT
-2 606.2
3-Years Forward
EV/EBIT
17.1

See Also

Discover More